Related Experiment Video

Updated: Aug 24, 2026

Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down
08:59

Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down

Published on: December 11, 2017

Drug Resistance and Therapeutic Reversal Strategies in Ovarian, Cervical, and Endometrial Cancers

Tiange Xing1, Hongxi Liu1, Wenjing Yu2

  • 1The First Affiliated Hospital of Zhejiang Chinese Medical University (Zhejiang Provincial Hospital of Chinese Medicine).

Journal of Visualized Experiments : Jove
|August 22, 2026
PubMed

Insights

Gynecological cancers (GCs) show resistance to therapies. This review details drug resistance mechanisms and strategies to overcome them in ovarian, cervical, and endometrial cancers.

Area of Science:

  • Oncology
  • Molecular Biology
  • Genetics

Background:

  • Gynecological cancers (GCs) are a major cause of female cancer mortality worldwide.
  • Drug resistance significantly impairs treatment efficacy and patient survival in GCs.
  • Understanding resistance mechanisms is crucial for developing effective therapies.

Purpose of the Study:

  • To review drug resistance mechanisms in ovarian, cervical, and endometrial cancers.
  • To elucidate multi-level drug resistance mechanisms.
  • To synthesize corresponding reversal strategies.

Main Methods:

  • Comprehensive literature review of preclinical and clinical studies.
  • Analysis of drug resistance mechanisms across five key aspects.
  • Synthesis of six reversal strategies based on identified mechanisms.

Main Results:

  • Drug resistance in GCs involves dysregulation in DNA damage repair (DDR), signaling pathways, epigenetics, drug transport, and the tumor microenvironment (TME).
  • Six reversal strategies include DDR inhibition, pathway intervention, epigenetic regulation, drug transport modulation, TME interventions, and emerging technologies.
  • Evidence spans from preclinical research to clinical trials.

Conclusions:

  • Multifaceted drug resistance mechanisms in GCs require integrated therapeutic approaches.
  • Current therapies have limitations, necessitating further investigation into novel strategies.
  • Developing new treatments based on a deeper understanding of resistance is essential for improving patient outcomes.

More Related Videos

Implementation of In Vitro Drug Resistance Assays: Maximizing the Potential for Uncovering Clinically Relevant Resistance Mechanisms08:46

Implementation of In Vitro Drug Resistance Assays: Maximizing the Potential for Uncovering Clinically Relevant Resistance Mechanisms

Published on: December 9, 2015

Tropomodulin 3 Overexpression as a Marker for Platinum Resistance and Immune Infiltration in Ovarian Cancer09:40

Tropomodulin 3 Overexpression as a Marker for Platinum Resistance and Immune Infiltration in Ovarian Cancer

Published on: August 2, 2024

Related Concept Videos

Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Adaptive Mechanisms in Cancer Cells02:53

Adaptive Mechanisms in Cancer Cells

Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...